Article

A Nanoparticle RIG-I Agonist for Cancer Immunotherapy

2023-04-25

Abstract excerpt

Pharmacological activation of the retinoic acid-inducible gene I (RIG-I) pathway holds promise for increasing tumor immunogenicity and improving response to immune checkpoint inhibitors (ICI). However, the potency and clinical efficacy of 5’-triphosphate RNA (3pRNA) agonists of RIG-I is hindered by multiple pharmacological barriers, including poor pharmacokinetics, nuclease degradation, and inefficient delivery to...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 373a3e3f-c1e2-5706-b655-7652ee84630e
DOI: 10.1101/2023.04.25.537919

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A Nanoparticle RIG-I Agonist for Cancer ImmunotherapyDOI 10.1101/2023.04.25.537919Read

RIG-I activating immunostimulatory RNA boosts the efficacy of anticancer vaccines and synergizes with immune checkpoint blockadeSemantic proximity Read

RIG-I immunotherapy overcomes radioresistance in p53-positive malignant melanomaSemantic proximity Read

RIG-I is an intracellular checkpoint that limits CD8+ T-cell antitumor immunitySemantic proximity Read

Nanomedicine for Cancer and Autoimmune ImmunotherapySemantic proximity Read

Tumor cell intrinsic RIG-I activation co-opts the host microenvironment to drive immune mediated tumor rejectionSemantic proximity Read

Enhanced lung delivery of an immunostimulatory duplex RNA augments the antitumor activity by reshaping systemic cytokine pharmacodynamicsSemantic proximity Read

CDK4/6 inhibition and dsRNA sensor agonism co-operate to enhance anti-cancer effects through ER stress and immune modulation of tumour cellsSemantic proximity Read

The Innate Immune Signalling Pathways: Turning RIG-I Sensor Activation against CancerSemantic proximity Read

Comb-structured mRNA vaccine tethered with short double-stranded RNA adjuvants maximizes cellular immunity for cancer treatmentSemantic proximity Read

RIG-I RNA agonist activates immunostimulatory macrophages to enhance checkpoint immunotherapy for glioblastomaSemantic proximity Read

TLR7 and RIG-I dual-adjuvant loaded nanoparticles drive broadened and synergistic responses in dendritic cells <i>in vitro</i> and generate unique cellular immune responses in influenza vaccinationSemantic proximity Read

Advances in Cancer Treatment through Nanotheranostics and Emerging TherapiesSemantic proximity Read